Background: Although diphenhydramine is frequently used to treat pruri
tus and nausea in patients who have received neuraxial opioids, there
are no data regarding its effect on ventilatory control. We conducted
the current study to evaluate the effects of diphenhydramine on hyperc
apnic and hypoxic ventilatory control in healthy volunteers. Methods:
First, we measured the steady-state ventilatory response to carbon dio
xide during hyperoxia with an end-tidal carbon dioxide tension of 46 o
r 54 mmHg (alternate subjects) in eight healthy volunteers. We then de
termined the hypoxic ventilatory response during isocapnic rebreathing
at the same carbon dioxide tension. After a 10-min recovery period, w
e repeated the steady-state and hypoxic ventilatory response measureme
nts at the other carbon dioxide tension (54 or 46 mmHg). Ten minutes a
fter subjects received diphenhydramine 0.7 mg.kg(-1) intravenously, we
repeated this sequence of ventilatory measurements. Results: Under hy
peroxic conditions (inspired oxygen fraction > 0.5) diphenhydramine di
d not affect the ventilatory response to hypercapnia. Similarly, at an
end-tidal carbon dioxide tension of 46 mmHg, neither the slope nor th
e position of the hypoxic ventilatory response curve changed significa
ntly after diphenhydramine. However, at an end-tidal carbon dioxide te
nsion of 54 mmHg, the slope of the hypoxic ventilatory response increa
sed from 1.28 +/- 0.33 to 2.13 +/- 0.61 1.min(-1).% Sp(O2)(-1)(mean +/
- standard error), and V-E, at an arterial hemoglobin oxygen saturatio
n of 90% increased from 31.2 +/- 3.1 to 43.1 +/- 5.41.min(-1)). Conclu
sions: We conclude that although it did not affect the ventilatory res
ponse to carbon dioxide during hyperoxia or the ventilatory response t
o hypoxia at an end-tidal carbon dioxide tension of 46 mmHg diphenhydr
amine augmented the hypoxic response under conditions of hypercapnia i
n our young healthy volunteers. Although these findings may help to ex
plain the apparent safety of diphenhydramine, they may not be applicab
le to debilitated patients or those who have received systemic or neur
axial ventilatory depressants.